TAVR Still Gaining Ground Among Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with severe aortic stenosis and high surgical risk, and it should be considered as an option for intermediate-risk patients. In recent years, the number of low-risk patients treated with TAVR has increased. This study analyzes low-risk patients from the German Aortic Valve Registry (GARY) who underwent isolated TAVR vs. surgical treatment.

All patients with a Society of Thoracic Surgeons (STS) score <4% between 2014 and 2015 were analyzed. The result was a total of 20,549 subjects: 14,487 underwent surgery and 6062 underwent TAVR.

Patients who underwent TAVR were significantly older and had more comorbidities, so propensity score matching was used to compare in-hospital mortality at 30 days and at 1 year.

TAVR patients showed significantly higher survival rates, both in-hospital and at 30 days, than patients who underwent conventional surgery (in-hospital survival for TAVR vs. surgery: 98.5% vs. 97.3%; p = 0.003; 30-day survival for TAVR vs. surgery: 98.1% vs. 97.1%; p = 0.014).


Read also: Is Alcohol Good, Bad, or Neutral for Cardiovascular Health?


At one year, mortality was similar for both methods (90.0% vs. 91.2%; p = 0.158).

Conclusion

This first GARY Registry analysis of low-risk patients showed similar mortality for surgery and transcatheter aortic valve replacement.

ehy699-libre-para-subir

Original Title: Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY).

Reference: Raffi Bekeredjian et al. European Heart Journal (2019) 40, 1323–1330.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...